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Abstract
Cardiomyopathies (CMs) encompass a heterogeneous group of structural and 
functional (systolic and diastolic) abnormalities of the myocardium and are either 
confined to the cardiovascular system or are part of a systemic disorder. CMs 
represent a leading cause of morbidity and mortality and account for a signifi-
cant percentage of death and cardiac transplantation. The 2006 American Heart 
Association (AHA) classification grouped CMs into primary (genetic, mixed, or 
acquired) or secondary (i.e., infiltrative or autoimmune). In 2008, the European 
Society of Cardiology classification proposed subgrouping CM into familial or 
genetic and nonfamilial or nongenetic forms. In 2013, the World Heart Federation 
recommended the MOGES nosology system, which incorporates a morpho-func-
tional phenotype (M), organ(s) involved (O), the genetic inheritance pattern (G), 
an etiological annotation (E) including genetic defects or underlying disease/sub-
strates, and the functional status (S) of a particular patient based on heart failure 
symptoms. Rapid advancements in the biology of cardio-genetics have revealed 
substantial genetic and phenotypic heterogeneity in myocardial disease. Given the 
variety of disciplines in the scientific and clinical fields, any desired classification 
may face challenges to obtaining consensus. Nonetheless, the heritable phenotype-
based CM classification offers the possibility of a simple, clinically useful diagnostic 
scheme. In this chapter, we will describe the genetic basis of dilated cardiomyopathy 
(DCM), hypertrophic cardiomyopathy (HCM), arrhythmogenic cardiomyopathy 
(ACM), LV noncompaction cardiomyopathy (LVNC), and restrictive cardiomy-
opathy (RCM). Although the descriptive morphologies of these types of CM differ, 
an overlapping phenotype is frequently encountered within the CM types and 
arrhythmogenic pathology in clinical practice. CMs appear to originate secondary 
to disruption of “final common pathways.” These disruptions may have purely 
genetic causes. For example, single gene mutations result in dysfunctional protein 
synthesis causing downstream dysfunctional protein interactions at the level of the 
sarcomere and a CM phenotype. The sarcomere is a complex with multiple protein 
interactions, including thick myofilament proteins, thin myofilament proteins, and 
myosin-binding proteins. In addition, other proteins are involved in the surround-
ing architecture of the sarcomere such as the Z-disk and muscle LIM proteins. One 
or multiple genes can exhibit tissue-specific function, development, and physi-
ologically regulated patterns of expression for each protein. Alternatively, multiple 
mutations in the same gene (compound heterozygosity) or in different genes 
(digenic heterozygosity) may lead to a phenotype that may be classic, more severe, 
or even overlapping with other disease forms.
Keywords: Inherited cardiovascular disease, Syndromic cardiovascular disease, 
Gene variants, Gene disorders, Genetic syndrome, Pathogenic mutation, Heritable 
cardiomyopathy, Sarcomeric cardiomyopathy, Metabolic disorders, Neuromuscular 
disease
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1. Introduction
Cardiomyopathies (CMs) encompass a heterogeneous group of structural and 
functional (systolic and diastolic) abnormalities of the myocardium and are either 
confined to the cardiovascular system or are part of a systemic disorder. CMs 
represent a leading cause of morbidity and mortality and account for a significant 
percentage of death and cardiac transplantation [1]. The 2006 American Heart 
Association (AHA) classification grouped CMs into primary (genetic, mixed, or 
acquired) or secondary (i.e., infiltrative or autoimmune). In 2008, the European 
Society of Cardiology classification proposed subgrouping CM into familial or 
genetic and nonfamilial or nongenetic forms. In 2013, the World Heart Federation 
recommended the MOGES nosology system, which incorporates a morpho-
functional phenotype (M), organ(s) involved (O), the genetic inheritance pattern 
(G), an etiological annotation (E) including genetic defects or underlying disease/
substrates, and the functional status (S) of a particular patient based on heart 
failure symptoms [2–4]. Rapid advancements in the biology of cardio-genetics have 
revealed substantial genetic and phenotypic heterogeneity in myocardial disease. 
Given the variety of disciplines in the scientific and clinical fields, any desired 
classification may face challenges to obtaining consensus. Nonetheless, the heritable 
phenotype-based CM classification offers the possibility of a simple, clinically 
useful diagnostic scheme (for an example, see [5]). In this chapter, we will describe 
the genetic basis of dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 
(HCM), arrhythmogenic cardiomyopathy (ACM), LV noncompaction cardiomy-
opathy (LVNC), and restrictive cardiomyopathy (RCM). Although the descriptive 
morphologies of these types of CM differ, an overlapping phenotype is frequently 
encountered within the CM types and arrhythmogenic pathology in clinical prac-
tice. CMs appear to originate secondary to disruption of “final common pathways.” 
These disruptions may have purely genetic causes. For example, single gene muta-
tions result in dysfunctional protein synthesis causing downstream dysfunctional 
protein interactions at the level of the sarcomere and a CM phenotype. The sarco-
mere is a complex with multiple protein interactions, including thick myofilament 
proteins, thin myofilament proteins, and myosin-binding proteins. In addition, 
other proteins are involved in the surrounding architecture of the sarcomere such as 
the Z-disk and muscle LIM proteins (Figure 1). One or multiple genes can exhibit 
tissue-specific function, development, and physiologically regulated patterns of 
expression for each protein. Alternatively, multiple mutations in the same gene 
(compound heterozygosity) or in different genes (digenic heterozygosity) may lead 
to a phenotype that may be classic, more severe, or even overlapping with other 
disease forms.
Figure 1. 






DCM is mainly characterized by left or biventricular dilatation, increased LV 
mass, and decreased systolic function (Figure 2) [6]. DCM can present with the 
clinical syndrome of systolic heart failure or with or without associated arrhythmias 
or thrombo-embolic disease. Additionally, DCM can be detected in asymptomatic 
individuals. Globally, DCM is the most common form of CM and the leading cause 
of heart transplantation in children and adults. The estimated incidence in the 
pediatric population is between 0.34 to 1.13 cases per 100,000 children per year with 
differences in demographic characteristics [7]. DCM has many known etiologies with 
many more to be discovered. Unfortunately, in many cases, no etiology can be found, 
and the CM is deemed idiopathic. Still, 25 to 50% of patients with idiopathic DCM 
have a positive family history, suggesting an underlying genetic predisposition [8]. 
The majority of genetically triggered cases of DCM are transmitted in an autosomal 
dominant pattern exhibiting variable penetrance. Other forms of inheritance include 
autosomal recessive, X-linked, and mitochondrial (maternally inherited), which are 
more frequent in the pediatric population [2]. Familial DCM occurs in 20 to 60% of 
cases, where approximately 40% of those cases may have a primary monogenic basis. 
However, this percentage is a variable approximation as a more critical evaluation 
of the genes linked to DCM continues to evolve and certain types of variations are 
Figure 2. 
Two-dimensional, apical 4-chamber echocardiographic image depicting an enlarged ventricle with spherical 
geometry and biatrial enlargement secondary to atrioventricular valve insufficiency in a patient with dilated 
cardiomyopathy.
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excluded from being certified as pathogenic [8]. Another conventional classification 
of DCM is based on the presence or absence of systemic disease. Thus, dividing DCM 
into syndromic and non-syndromic forms is a practical approach to evaluating this 
highly heterogeneous disease. The diagnostic rate for gene testing in non-syndromic 
DCM is 46 to 73% [9], but this estimation may likely be confounded by insufficient 
control for population variation. Over the past decade, 47 new genes (for a total of 
60 different genes) have been linked to DCM in the Human Gene Mutation Database 
(HGMD), see Table 1. From these genes, a large-scale analysis revealed truncating 
variants in the titin gene (TNN) were the most common pathogenic mutations in 
non-syndromic DCM [10, 11]. Other core-causative genes include MYH7 (encoding 
beta myosin heavy chain), TNNT2 (encoding troponin T2), LMNA (encoding a 
nuclear envelope protein, lamin A/C), and TPM1 (encoding Tropomyosin 1). Other 
rare pathogenic variants (minor allele frequency) implicated in non-syndromic 
DCM include genes coding for the sarcomere and Z-disk (i.e., actin, myosin-binding 
protein C3, myopalladin, nebulette, ZASP), cytoskeleton (i.e., dystrophin, desmin), 
nuclear envelope (emerin), mitochondria (i.e., Tafazzin), sarcoplasmic reticulum, 
desmosomes, ion channels, and transcription factors [9, 12, 13].
Regardless of the mode of inheritance, pathogenic gene variants result in a 
cardiomyocyte milieu susceptible to stress, leading to downstream dysfunction of 
the contractile apparatus and heart failure, “the final common pathway” hypothesis 
[14]. The term “familial DCM” is frequently applied in the presence of DCM in two 
or more first-degree relatives. The incidence is likely underestimated due to the 
diversity of inheritance patterns, timing of presentation, variable penetrance, and 
lack of symptoms in subclinical disease [15, 16].
2.1.1 Autosomal dominant dilated cardiomyopathy
The most common form of familial DCM is inherited in an autosomal dominant 
pattern [6]. In this sub-type, arrhythmias associated with DCM (DCM-A) are fre-
quently encountered [17]. Genetic heterogeneity exists with at least 30 unique genes 
identified in familial non-arrhythmogenic DCM and five genes for DCM-A [17, 18].
2.1.2 X-linked Cardiomyopathy (XLCM)
XLCM has been reported as an isolated disease of the heart or associated with 
skeletal myopathy such as with Duchenne muscular dystrophy (DMD) or Becker 
muscular dystrophy (BMD). All skeletal myopathies are frequently associated with 
the development of DCM and/or DCM-A. The causative gene codes for the protein 
dystrophin located at the short arm of the X chromosome at Xp21. Dystrophin is a 
cytoskeletal protein that provides structural support to the cardiomyocyte and plays 
a major role in linking the sarcomeric contractile apparatus to the sarcolemma and 
extracellular matrix (ECM) [19, 20]. DMD and BMD are severe muscular dystro-
phies of childhood, affecting ~1 in 3,500 males for DMD and 1 in 300,000 males for 
BMD. Typically, DMD and BMD are characterized by skeletal myopathy, elevated 
serum creatine kinase, and calf pseudo-hypertrophy. DMD is the more severe 
form due to the absence of functional dystrophin, leading to muscle weakness by 
3 years of age and wheelchair dependence by 12 years of age [21]. Cardiac involve-
ment varies with age but is nearly universal by 20 years in all DMD patients. The 
onset of clinical features starts later in life in BMD than in DMD. Histologic studies 
show cardiac muscle replacement with fibrosis. This fibrosis eventually leads to 
ventricular dysfunction/enlargement and is associated with conduction system 
abnormalities and ventricular arrhythmias. Molecular analysis of the DMD gene is 




















Gene Protein Pattern of Inheritance Disease Association OMIM# Locus
ABCC9 ATP-Binding Cassette, Subfamily C, Member 9 AD DCM 601439 14q12-q22
ACTC1 Actin, Alpha, Cardiac Muscle AD DCM, LVNC, ACM, 
HCM
102540 5q31.1
ACTN2 Actinin, Alpha-2 AD DCM, HCM 102573 6q22.1
AKAP9 A-Kinase Anchor Protein 9 AD DCM 604001 2q32.1-q32.3
ALMS1 Centrosome and Basal Body Associated Protein AR DCM 606844 10p14-p12
ALPK3 Alpha Kinase 3 AR DCM, HCM 617608 1p36.32
ANKRD1 Ankyrin Repeat Domain-Containing Protein 1 AD DCM, HCM 609599 7q36.1
BAG3 Bcl2-Associated Athanogene 3 AD DCM, RCM, HCM 603883 14q24.3
CASQ2 Calsequestrin 2 AR, AD DCM, LVNC 114251 6q22.31
CAV3 Caveolin 3 AD DCM, HCM 601253 12q24.13
CHRM2 Cholinergic Receptor, Muscarinic, 2 AD DCM 118493 10q25.2-q26.2
CRYAB Crystallin, Alpha-B AD DCM 123590 11q23.1
CSRP3 Cysteine- And Glycine-Rich Protein 3 AD DCM, HCM 600824 12p12.1
CTF1 Cardiotrophin 1 AR, AD DCM 600435 1p13.1
DES Desmin AD,AR DCM, ACM, RCM 125660 17q21
DMD Dystrophin XL DCM 300377 3p25.3
DOLK Dolichol Kinase AR DCM 610746 7q33
DSC2 Desmocollin 2 AD, AR DCM, ACM 600271 Xq22
DSG2 Desmoglein 2 AD DCM, ACM 125671 15q24.1
DSP Desmoplakin AD, AR DCM, ACM 125485 11p15.5
DTNA Dystrobrevin Alpha AD DCM, LVNC 601239 2q31












Gene Protein Pattern of Inheritance Disease Association OMIM# Locus
EYA4 Eyes Absent, Drosophila, Homolog Of, 4 AD DCM 603550 11p15.1
FHL1 Four-And-A-Half LIM Domains 1 XL DCM, HCM 300163 15q22.31
FHL2 Four-And-A-Half LIM Domains 2 Unknown DCM 602633 16p11.2
FKRP Fukutin-Related Protein AR DCM 606596 10q21.3
FKTN Fukutin AR DCM 607440 2q35
FLNC Filamin C AD DMC, RCM, HCM, ACM 102565 10q22.2
GATA4 Gata-Binding Protein 4 AD DCM 600576 Xq21.2-p21.1
GATAD1 Gata Zinc Finger Domain-Containing Protein 1 AR DCM 614518 9q34.11
GLA Galactosidase, Alpha XL DCM, HCM 300644 18q11.2
ILK Integrin-Linked Kinase AD DCM 602366 18q12.1
JUP Junction Plakoglobin AD, AR DCM, ACM 173325 2p13.1
LAMA4 Laminin, Alpha-4 AD DCM 600133 18q12.1
LAMP2 Lysosome-Associated Membrane Protein 2 XL DCM, HCM 309060 3p25.2
LDB3 Lim Domain-Binding 3 AD DCM, LVNC, ACM, 
HCM
605906 2p22.1
LMNA Lamin A/C AD, AR DCM, LVNC, ACM, 
HCM
150330 1q22
LRRC10 Leucine-Rich Repeat-Containing Protein 10 AD, AR DCM 610846 4q21.3
MURC/CAVIN4 Muscle-Related Coiled-Coil Protein/Caveolae-Associated 
Protein 4
AD DCM 617714 18q12.1
MYBPC3 Myosin-Binding Protein C, Cardiac AD DCM, LVNC, RCM, 
HCM
600958 Xq28




















Gene Protein Pattern of Inheritance Disease Association OMIM# Locus
MYH7 Myosin, Heavy Chain 7, Cardiac Muscle, Beta AD DCM, LVNC, RCM, 
HCM
160760 7p14.2
MYL2 Myosin, Light Chain 2, Regulatory, Cardiac, Slow AD DCM, HCM 160781 3p21.3-p21.2
MYL3 Myosin, Light Chain 3, Alkali, Ventricular, Skeletal, Slow AD, AR DCM, HCM, RCM 160790 1q32
MYLK2 Myosin Light Chain Kinase 2 AD DCM, HCM 606566 20q13.31
MYOT Myotilin AD DCM 604103 Xq28
MYOZ2 Myozenin 2 AD DCM, RCM, HCM 605602 3p25.1
MYPN Myopalladin AD DCM, RCM, HCM 608517 12q23.1
NEBL Nebulette AD DCM 605491 6q23.2
NEXN Nexilin (F Actin Binding Protein) AD DCM, HCM 613121 1q22
NKX2-5 Nk2 Homeobox 5 AD DCM 600584 Xq26.3
PDLIM3 Pdz And Lim Domain Protein 3 AD DCM, HCM 605899 1q43
PKP2 Plakophilin 2 AD DCM, ACM 602861 11p15.4
PLN Phospholamban AD DCM, ACM, HCM 172405 4q12
PRDM16 Pr Domain-Containing Protein 16 AD DCM, LVNC 605557 6q21
PRKAG2 Protein Kinase, Amp-Activated, Noncatalytic, Gamma-2 AD DCM, HCM 602743 4q26-q27
RBM20 RNA-Binding Motif Protein 20 AD DCM 613171 2q12.2
RYR2 Ryanodine Receptor 2 (Cardiac) AD DCM, HCM, ACM 180902 12p11
SCN5A Sodium Channel, Voltage-Gated, Type V, Alpha Subunit AD DCM, ACM 600163 20q13.12
SGCA Sarcoglycan Alpha AR DCM 600119 1q25.2
SGCB Sarcoglycan Beta AR DCM 600900 15q22.1
SGCD Sarcoglycan, Delta (35kda Dystrophin-Associated 
Glycoprotein)












Gene Protein Pattern of Inheritance Disease Association OMIM# Locus
SLC25A4 Solute Carrier Family 25, Member 4 (Mitochondrial 
Carrier Adenine Nucleotide Translocator)
AD, AR DCM 103220 7q21-q22
TAZ Tafazzin AR, XL DCM, LVNC 300394 Xq24
TBX20 T-Box 20 AD DCM, LVNC 606061 10q22.3-q23.2
TCAP Titin-Cap (Telethonin) AR DCM, HCM 604488 3p21
TMEM43 Transmembrane Protein 43 AD DCM, ACM 612048 10q23.3
TMPO Thymopoietin AD DCM 188380 9q31.2
TNNC1 Troponin C Type 1 (Slow) AD DCM, HCM 191040 17q21.33
TNNI3 Troponin I Type 3 (Cardiac) AD DCM, RCM, HCM 191044 3p21.1
TNNT2 Troponin T Type 2 (Cardiac) AD DCM, LVNC, RCM, 
HCM
191045 17q12
TOR1AIP1 Torsin-1a-Interacting Protein 1 AR DCM 614512 7q32.1
TPM1 Tropomyosin 1 (Alpha) AD DCM, RCM, HCM 191010 19q13.4
TRDN Triadin AR DCM 603283 17q25.3
TTN Titin AD, AR DCM, ACM, HCM 188840 5q33-q34
TTR DCM AD DCM 176300 18q12.1
TXNRD2 Thioredoxin Reductase 2 AD, AR DCM 606448 8p23.1
VCL Vinculin AD DCM, LVNC, HCM 193065 10q25.2
AD – Autosomal dominant; AR – Autosomal Recessive; XL – X-linked; DCM – Dilated cardiomyopathy; HCM – Hypertrophic cardiomyopathy; LVNC – Left ventricular non-compaction cardiomyopathy; 
ACM – Arrhythmogenic cardiomyopathy; RCM – Restrictive cardiomyopathy.
Table 1. 




be considered for Western blot and immunohistochemistry studies, although this is 
rarely performed in current clinical practice [19, 20, 22–24]. Although less severe, 
female carriers with clinical DMD and BMD are also at risk to develop DCM but at 
a later age. Hence, a complete cardiac evaluation for carrier females every 3-5 years 
starting in adolescence or early adulthood is warranted with concomitant appropri-
ate medical treatment if indicated [25].
2.1.3 Isolated X-Linked Dilated Cardiomyopathy
Isolated XLCM is characterized by consistent early expression and rapid 
progression of CM in males during childhood, later onset with slower progres-
sion in females, and no male-to-male transmission [26]. Linkage analysis of 
X-chromosome-specific DNA markers performed in suspected individuals 
demonstrated preferential involvement of cardiac muscle and normal dystrophin 
by Western blotting in skeletal muscle of the same affected individuals [27]. The 
phenotype and pathologic features described in this population do not differ from 
those in patients with DCM. Hence, the medical management should be provided 
according to the current heart failure guidelines.
2.1.4 Emery-Dreifuss Muscular Dystrophy
Emery-Dreifuss muscular dystrophy (EDMD), also known as humeroperoneal 
muscular dystrophy, is a heterogeneous disorder with X-linked recessive, autosomal 
dominant, and autosomal recessive forms of inheritance [28]. Several forms of 
this disease are considered nuclear envelopathies because they are associated with 
mutations in genes encoding nuclear membrane proteins, including the EMD gene 
encoding for emerin, the LMNA gene encoding for lamin A and lamin C, and the 
SYNE1 and SYNE2 genes encoding for nesprin 1 and nesprin 2, respectively [29]. 
The different forms of EDMD have identical symptoms that usually begin in the 
first or second decade of life. Extremity contractures are often the first manifesta-
tion. Muscle weakness and wasting has a humeroperoneal distribution and tends to 
be slowly progressive. DCM is seen in many patients with EDMD. This condition is 
typically associated with atrioventricular conduction abnormalities such as first-
degree atrioventricular block, sinus bradycardia, or supraventricular tachycardia, 
which may be early signs of cardiac involvement and may be progressive. Symptoms 
of hypoperfusion (syncope or near syncope) often result from infranodal or atrio-
ventricular conduction block with the development of slow junctional rhythms, 
which may require pacemaker placement [30]. The onset of cardiac abnormalities 
is usually in the third decade of life, but earlier onset during adolescence has been 
observed. Additionally, there is no correlation between the degree of neuromuscu-
lar involvement and the severity of cardiac abnormalities [31].
2.1.5 Barth Syndrome
Barth syndrome (BTS) is another X-linked cardioskeletal myopathy that 
encompasses abnormal mitochondrial function, short stature, cyclic neutropenia, 
cardiolipin deficiency, and variable degrees of 3-methylglutaconic aciduria. BTS is 
caused by mutations in the TAZ gene (previously called G4.5), which is located in 
the chromosome Xq28 region and encodes for the Tafazzin protein [32]. Pathologic 
gene variants may result in a wide variety of cardiac phenotypes including 
DCM, HCM, LVNC, and endocardial fibroelastosis. In many cases, affected 
infants succumb to heart failure, arrhythmias, or sepsis secondary to leukocyte 
dysfunction [33, 34].
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2.2 Hypertrophic cardiomyopathy
HCM is the second most prevalent CM in children, representing 40% of cases, 
with an estimated incidence of 0.47 in 100,000 children [35]. HCM is more preva-
lent in boys than in girls and in African American children than in Caucasian or 
Hispanic children. In the pediatric population, the incidence of HCM is 10 times 
higher in patients under 1 year of age than in older children [36]. HCM is a primary 
myocardial disorder with mainly an autosomal dominant pattern of inheritance 
characterized by hypertrophy of the left ventricle (with or without hypertrophy of 
the right ventricle) and histologic features of myocyte hypertrophy, myofibrillar 
disarray, and interstitial fibrosis. While asymmetric septal hypertrophy is the most 
common pattern of hypertrophy, the degree and location of hypertrophy vary. 
Some patients exhibit concentric hypertrophy, harbored in other walls or confined 
to the left ventricular apex (Figure 3) [37].
The clinical presentation of HCM is highly variable, ranging from asymptom-
atic hypertrophy, to symptomatic arrhythmias, to refractory heart failure due to 
diastolic dysfunction, or “burned-out HCM” with the development of systolic 
dysfunction. Notably, diastolic dysfunction can even be detected in individuals with 
HCM who have normal LV wall thickness, suggesting that diastolic dysfunction is 
an early feature of HCM rather than a secondary consequence of hypertrophy [38]. 
Categorization of HCM includes non-syndromic HCM (without other systemic 
involvement) and the syndromic form of HCM (in association with inborn errors of 
metabolism, malformation syndromes, and neuromuscular disorders) [39].
Figure 3. 
Two dimensional images of HCM in the parasternal short axis (A) exhibiting concentric hypertrophy with 
significant involvement of the interventricular septum (IVS) and corroborated by the parasternal long axis 




Approximately 20–30% of individuals with non-syndromic HCM and no family 
history of HCM harbor a pathogenic variant in a known gene encoding a compo-
nent of the sarcomere. However, 50–60% of adults and children with a positive 
family history of HCM harbor a pathogenic gene variant. Furthermore, 3–5% of 
affected individuals have more than one sarcomere gene variant (either biallelic 
variants in 1 gene or heterozygous variants in >1 gene) [40, 41].
2.2.1 Non-syndromic Hypertrophic Cardiomyopathy
More than two decades ago, the first chromosome locus (14q11.2-q12) encod-
ing components of the sarcomere (beta-myosin heavy chain) was elucidated as 
the pathogenic basis for familial HCM [42]. Since then, more than 1,400 muta-
tions in 27 identified genes have been associated with HCM, see Table 2 [43]. 
The vast majority have autosomal dominant transmission, but mitochondrial 
and autosomal recessive patterns have been also described [44–46]. Most of the 
disease-causing mutations implicated in HCM include mutations in the MYH7 
gene (encoding beta-myosin heavy chain) and in the MYBPC3 gene (encoding 
cardiac myosin-binding protein C). These mutations account individually for 
40%, and the remaining genes (TNNT2, TPM1, ACTC1, TNNI3, TTN, MYL2, and 
others) account collectively for 10% of cases [47]. Most of these mutations involve 
missense mutations (resulting in a direct amino acid change) and frameshift-type 
mutations (insertions or deletions of the number of nucleotides), which alter the 
properties of the protein involved. The prevalence of causal genes varies among 
different populations. Collective results of genetic epidemiologic studies suggest 
that up to 70% of the causal genes in familial cases and up to 40% in sporadic 
HCM cases have a genetic mutation identified [44–46]. In our experience in the 
past 10 years, approximately 70% of non-infantile individuals have an identifiable 
mutation in a sarcomere-encoding gene, whereas fewer mutations (approximately 
20%) are identified in infants.
Mouse models of sarcomeric mutations have shown changes in cardiac chem-
istry and diastolic function well before myocardial hypertrophy is observed [48]. 
Moreover, the genetic defect in a gene encoding for a sarcomeric protein may 
disrupt normal contraction and relaxation with dysregulation of calcium in the 
sarcomere. Thus, reduced calcium reuptake and decreased stores in the sarcoplas-
mic reticulum will trigger a remodeling process by several transcription factors, 
resulting in the hypertrophy of the cardiomyocytes and increased energy demand, 
which eventually results in ischemia, fibrosis, and death [44]. There is no reliable 
correlation between the genotype and phenotype among the identified sarcomeric 
mutations, except for those patients harboring multiple mutations [49].
2.2.2 Syndromic hypertrophic cardiomyopathy
HCM has been associated with multiple phenotypically distinct disorders. 
Improvements in sequencing technologies and phenotypic characterization and the 
incorporation of epigenetics have expanded our understanding of syndromic CMs.
2.2.2.1 RAS/MAPK pathway syndromes
Since the discovery of the first gene (PTPN11) associated with Noonan 
syndrome in 2001, multiple genes (RAF1, SOS1, KRAS, NRAS, BRAF, MAP2K1 
[MEK1], MAP2K2 [MEK2], HRAS, and SHOC2) have been identified in the RAS/
mitogen-activated protein kinase (MAPK) pathway. This pathway is important 












Gene Protein Pattern of Inheritance Disease Association OMIM# Locus
ACTC1 Actin, Alpha, Cardiac Muscle AD HCM, DCM, LVNC, ACM 102540 5q31.1
ACTN2 Actinin, Alpha-2 AD HCM, DCM 102573 6q22.1
ALPK3 Alpha Kinase 3 AR HCM, DCM 617608 1p36.32
ANKRD1 Ankyrin Repeat Domain-Containing Protein 1 AD HCM, DCM 609599 7q36.1
BAG3 Bcl2-Associated Athanogene 3 AD HCM, DCM, RCM 603883 14q24.3
BRAF V-Raf Murine Sarcoma Viral Oncogene Homolog B1 AD HCM 164757 12q15
CAV3 Caveolin 3 AD HCM, DCM 601253 12q24.13
CSRP3 Cysteine- And Glycine-Rich Protein 3 AD HCM, DCM 600824 12p12.1
FHL1 Four-And-A-Half LIM Domains 1 XL HCM 300163 15q22.31
FLNC Filamin C AD HCM, ACM, DMC, RCM 102565 10q22.2
GAA Glucosidase, Alpha, Acid AR HCM 606800 19p13.3
GLA Galactosidase, Alpha XL HCM 300644 18q11.2
HRAS V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog AD HCM 190020 9q31.1
JPH2 Junctophilin 2 AD HCM 605267 11p11.2
KRAS V-Ki-Ras2 AD HCM 190070 14q12
LAMP2 Lysosome-Associated Membrane Protein 2 XL HCM, DCM 309060 3p25.2
LDB3 Lim Domain-Binding 3 AD HCM, DCM, LVNC, ACM 605906 2p22.1
LMNA Lamin A/C AD, AR HCM, DCM, LVNC, ACM 150330 1q22
MAP2K1 Mitogen-Activated Protein Kinase Kinase 1 AD HCM 176872 14q12
MAP2K2 Mitogen-Activated Protein Kinase Kinase 2 AD HCM 601263 12q24.11
MYBPC3 Myosin-Binding Protein C, Cardiac AD HCM, DCM, LVNC, RCM 600958 Xq28



















Gene Protein Pattern of Inheritance Disease Association OMIM# Locus
MYH7 Myosin, Heavy Chain 7, Cardiac Muscle, Beta AD HCM, DCM, LVNC, RCM 160760 7p14.2
MYL2 Myosin, Light Chain 2, Regulatory, Cardiac, Slow AD HCM 160781 3p21.3-p21.2
MYL3 Myosin, Light Chain 3, Alkali, Ventricular, Skeletal, Slow AD, AR HCM, RCM 160790 1q32
MYLK2 Myosin Light Chain Kinase 2 AD HCM 606566 20q13.31
MYOM1 Myomesin 1 AD HCM 603508 18p11.31
MYOZ2 Myozenin 2 AD HCM, DCM, RCM 605602 3p25.1
MYPN Myopalladin AD HCM, DCM, RCM 608517 12q23.1
NEXN Nexilin (F Actin Binding Protein) AD HCM, DCM 613121 1q22
NRAS Neuroblastoma Ras Viral Oncogene Homolog AD HCM 164790 5q31.2
PDLIM3 Pdz And Lim Domain Protein 3 AD HCM, DCM 605899 1q43
PLN Phospholamban AD HCM, DCM, ACM 172405 4q12
PRKAG2 Protein Kinase, Amp-Activated, Noncatalytic, Gamma-2 AD HCM 602743 4q26-q27
PTPN11 Protein-Tyrosine Phosphatase, Nonreceptor-Type, 11 AD HCM 176876 10q21.3
RAF1 V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1 AD HCM 164760 10p12
RIT1 Ras-Like Without Caax 1 AD HCM 609591 1p31.1
RYR2 Ryanodine Receptor 2 (Cardiac) AD HCM, ACM 180902 12p11
SHOC2 Soc-2 Homolog AD HCM 602775 5q35.1
SOS1 Son Of Sevenless, Drosophila, Homolog 1 AD HCM 182530 1p13.2
TCAP Titin-Cap (Telethonin) AR HCM, DCM 604488 3p21
TNNC1 Troponin C Type 1 (Slow) AD HCM, DCM 191040 17q21.33
TNNI3 Troponin I Type 3 (Cardiac) AD HCM, DCM, RCM 191044 3p21.1
TNNT2 Troponin T Type 2 (Cardiac) AD HCM, DCM, LVNC, RCM 191045 17q12












Gene Protein Pattern of Inheritance Disease Association OMIM# Locus
TTN Titin AD, AR HCM, DCM, ACM 188840 5q33-q34
TTR Transthyretin AD HCM 176300 4q35.1
VCL Vinculin AD HCM, DCM, LVNC 193065 10q25.2
AD – Autosomal dominant; AR – Autosomal Recessive; XL – X-linked; DCM – Dilated cardiomyopathy; HCM – Hypertrophic cardiomyopathy; LVNC – Left ventricular non-compaction cardiomyopathy; 
ACM – Arrhythmogenic cardiomyopathy; RCM – Restrictive cardiomyopathy.
Table 2. 




a spectrum of disorders known as “RASopathies” including Noonan and Noonan-
like syndromes such as LEOPARD, Costello, and cardiofaciocutaneous syndrome 
(CFC) [50].
The management of RASopathies should involve a multidisciplinary team with 
expertise in the assessment of cardiac structural defects, HCM, and arrhythmias. 
Surveillance with periodic echocardiography (HCM), electrocardiography (rhythm 
disturbances), neurologic and eye examination, evaluation for scoliosis, and assess-
ment of growth and cognitive development is also recommended.
2.2.2.1.1 Noonan syndrome
Noonan syndrome is relatively common with a prevalence of ~1 in 3500 
people. This disease is inherited in an autosomal dominant pattern, although 
new cases are common because the de novo mutation rate is high. Clinical 
manifestations of Noonan syndrome include short stature, as well as dysmor-
phic features including hypertelorism, down-slanting palpebral fissures, low-set 
posteriorly rotated ears, lymphatic anomalies, and webbing of the neck. The 
estimated frequency of cardiac disease is 50 to 80%, and the disease is mainly 
characterized by pulmonary valve stenosis, branch pulmonary artery stenosis 
and Tetralogy of Fallot, in addition to HCM. PTPN11 gene mutations are more 
common in individuals with pulmonary stenosis, characteristic facial features, 
and short stature, while mutations in the RAF1 gene are associated with HCM 
in up to 95% of individuals [51]. The myocardial involvement in these patients 
is typically diagnosed during infancy with findings of asymmetric septal 
hypertrophy associated with myocyte disarray [52, 53]. With progression of the 
disease, the combination of biventricular outflow track obstruction is poorly 
tolerated and associated with increased mortality. Presentation during infancy 
without congestive heart failure is associated with a 70% three-year survival 
rate; when associated with congestive heart failure, the 6-month survival rate 
decreases to 30% [54].
Surgical relief of right ventricular outflow tract obstruction (RVOTO) is recom-
mended in patients with more than a mild degree of obstruction. Septal myectomy 
is also advised when left ventricular outflow tract obstruction (LVOTO) is associ-
ated with heart failure symptoms, although re-growth of the LVOTO is common 
when myectomy is performed in patients younger than one year of age. In some 
children, heart transplantation is necessary.
2.2.2.1.2 LEOPARD syndrome
LEOPARD syndrome, also called Noonan syndrome with multiple lentigines, 
is a rare autosomal dominant disorder caused by mutations in the protein tyrosine 
phosphatase gene, PTPN11. LEOPARD is an acronym for the major features of this 
disorder, including multiple lentigines, electrocardiogram conduction abnormali-
ties, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of 
growth, and sensorineural deafness [55]. Multiple lentigines, present in more than 
90% of patients, are the most prominent manifestation of LEOPARD syndrome. 
Lentigines appear during infancy and early childhood and increase in number 
over time to involve a large portion of the skin, including the face, neck, and upper 
trunk. The diagnosis of LEOPARD is difficult, given the highly variable expressiv-
ity of the syndrome. In the first year of life, before the appearance of lentigines, 
the diagnosis can be clinically suspected in infants presenting with characteristic 
facial features, HCM, and café-au-lait macules. The diagnosis can be confirmed by 
molecular screening for PTPN11 mutations [56].
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2.2.2.1.3 Costello syndrome
Costello syndrome is a rare disorder with substantial clinical overlap with other 
RASopathy syndromes. This disorder is caused by mainly de novo heterozygous 
mutations in the HRAS gene, with more than 90% of the mutations clustered in 
codons 12 and 13 [57]. Costello syndrome is characterized by failure-to-thrive in 
infancy, short stature, characteristic facial features, curly/sparse hair, papillomata, 
osteoporosis, malignancies (such as embryonal rhabdomyosarcoma), cardiovascu-
lar malformations (such as pulmonary stenosis and HCM), rhythm disturbances 
(such as multifocal atrial tachycardia), and neurological abnormalities including 
intellectual disability [58].
2.2.2.1.4 Cardiofaciocutaneous (CFC) syndrome
Cardiofaciocutaneous (CFC) syndrome also has substantial clinical overlap 
with other RASopathy syndromes because of its common ectodermal involve-
ment as well as findings of intellectual impairment and cardiac anomalies. Skin 
abnormalities can be extensive and include hyperkeratosis, eczema, palmoplantar 
hyperkeratosis, and keratosis pilaris. The hair is typically sparse and curly. CFC 
syndrome is characterized by cardiac abnormalities (pulmonary valve stenosis, 
other valve dysplasias, septal defects, HCM, and rhythm disturbances). HCM is 
identified in approximately 40% of cases and presents more commonly during 
infancy, but it can develop at any age [59]. Neoplasia, mostly acute lymphoblastic 
leukemia (ALL), has been reported in some individuals [50, 60]. Diagnosis is based 
on clinical findings and molecular genetic testing. Common genes associated with 
CFC syndrome include BRAF (~75%), MAP2K1 and MAP2K2 (~25%), and MEK2 
and KRAS (<2%) [61–63].
2.2.2.2 Metabolic disorders associated with cardiomyopathy
Congenital metabolic disorders result from absent or abnormal enzymes—or 
their cofactors—which can lead to accumulation or deficiency of a specific metabo-
lite. Although these disorders exhibit different modes of inheritance, most are 
transmitted in an autosomal recessive or mitochondrial pattern. The possibility of 
an inborn error of metabolism should be considered in infants, children, and young 
adults who present with any of the cardiovascular phenotypes or laboratory features 
described below. Optimal outcomes for children with these disorders depend upon 
early recognition of the signs and symptoms of metabolic disease, prompt evalu-
ation, and referral to a center with expertise in cardiovascular genetics. Delay in 
diagnosis may result in acute metabolic/hemodynamic decompensation, progres-
sive neurologic injury, or death.
2.2.2.2.1 Pompe disease
Pompe disease, also known as glycogen storage disease type II, is an autosomal 
recessive metabolic disorder that affects muscle and nerve cells throughout the 
body. This condition occurs secondary to accumulation of glycogen in lysosomes 
due to a deficiency of the lysosomal acid alpha-glucosidase enzyme. The build-up 
of glycogen leads to progressive myopathy and weakness throughout the body 
affecting various tissues including the liver, nervous system, and—most notably—
skeletal muscle and myocardium. The Pompe phenotype varies widely [64]. In the 
infantile form, muscles appear normal but are limp and weak, preventing normal 




aminotransferase (AST) are common. ECG reveals a short PR interval with giant 
QRS complexes in all leads, suggesting biventricular hypertrophy. As the disease 
progresses, HCM may result in cardiorespiratory failure. Without treatment, death 
usually occurs due to heart failure and respiratory weakness within the first year 
of life [65]. The juvenile and adult forms present with a variable age of onset. The 
primary clinical finding is skeletal myopathy with a more protracted course, leading 
to respiratory failure. Affected children usually present with delayed gross-motor 
development and progressive weakness in a limb-girdle distribution. Early involve-
ment of the diaphragm is a common feature leading to death in the second or third 
decade of life. In contrast to the infantile form, mild and non-specific cardiac 
abnormalities can be detected in patients with late-onset disease [66]. Enzyme 
replacement therapy usually results in decreased ventricular hypertrophy, reduced 
LV outflow tract obstruction, and normalization of the conduction system [67].
2.2.2.2.2 Danon disease
Danon disease, also known as glycogen storage disease type IIb, is an X-linked 
lysosomal and glycogen storage disorder associated with skeletal muscle weak-
ness and intellectual disability. Danon disease involves a genetic defect in the 
LAMP2 gene located at chromosome Xq24, which encodes the lysosome-associated 
membrane protein and alters the normal protein structure. While the function of 
the LAMP2 gene is not well understood, LAMP2 protein is primarily located in 
lysosomes. HCM and electrophysiologic abnormalities are the major cardiovascular 
consequences of glycogen accumulation with resultant myocardial degeneration. 
Ventricular preexcitation is encountered at a much higher frequency in Danon 
disease than in sarcomere-related HCM [68, 69]. The cardiac degeneration is usu-
ally appreciated clinically by the presence of HCM during childhood or adolescence 
with subsequent transition to a DCM phenotype with progressive heart failure 
[70]. Female carriers have also been described in this disorder and are attributed to 
unfavorable lyonization [71]. They commonly develop symptoms in their 30s to 40s 
and can be afflicted with DCM.
2.2.2.2.3 Fabry disease
Fabry disease is considered the most prevalent lysosomal storage disorder. This 
disease is an X-linked inborn error of the glycosphingolipid metabolic pathway and 
involves deficiency of the lysosomal hydrolase alpha-galactosidase A (alpha-Gal 
A) mapped to the long arm of the X chromosome (Xq22.1) [72]. Several hundred 
mutations in the GLA gene have been identified. Most cases are familial and few 
originate from de novo mutations [73]. Patients with Fabry disease may present with 
a spectrum of clinical manifestations, ranging from the severe classic phenotype 
in males to asymptomatic disease in females. The enzyme deficiency results in 
accumulation of glycosphingolipids in the lysosomes in nearly all cell types and 
tissues, leading to multisystem disease including neurologic (paresthesia and 
pain crises), dermatologic (angiokeratomas and telangiectasias), ophthalmologic 
(corneal dystrophy), renal (proteinuria and renal insufficiency), and cardiac 
manifestations by the second to fifth decades of life [74]. Cardiac disease is 
relatively common in Fabry disease. Patients may develop HCM (similar to that 
seen in sarcomeric HCM), arrhythmias, and valvar abnormalities. Management of 
cardiovascular symptoms and the prevention of complications rely on conventional 
pharmacologic and device-based therapies, but data on the effect of enzyme 
replacement therapy suggest it has the potential to attenuate and possibly reverse 
some aspects of cardiac involvement [75, 76].
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2.2.2.2.4 Friedreich’s ataxia
Friedreich’s ataxia is an autosomal recessive inherited disease with an 
estimated incidence of 1 in 50,000 in the general population. The genotype is 
characterized by trinucleotide repeat expansion of a normal codon affecting the 
protein frataxin, a mitochondrial inner membrane protein important for iron 
homeostasis. As the defect lies within an intron (which is removed from the 
mRNA transcript between transcription and translation), this mutation does not 
result in the production of abnormal frataxin. Instead, the mutation decreases 
the transcription of the gene through gene silencing. Low frataxin levels lead to 
insufficient biosynthesis of iron–sulfur clusters that are required for the mito-
chondrial electron transport chain to ultimately generate adenosine triphosphate 
(ATP). The major clinical manifestations of Friedreich’s ataxia include progressive 
neurologic dysfunction (gait ataxia, optic atrophy, loss of position and vibration 
sense), diabetes mellitus, and myocardial involvement. The cardiac phenotype 
is manifested by arrhythmias and HCM. Heart failure remains the leading cause 
of death in this population [77, 78]. HCM is seen in approximately two-thirds 
of patients with Friedreich’s ataxia, and one-third of those cases develop during 
childhood [79].
2.2.2.2.5 Mitochondrial cardiomyopathy
Mitochondria are the main energy source in cells due to the ability to perform 
oxidative phosphorylation via proteins in the mitochondrial respiratory chain. 
Several genes are involved in the role of cellular energy production. Mutations in 
these genes may result in severe involvement in organs that are heavily dependent 
on energy production, such as the brain, heart, and skeletal muscle. Mitochondrial 
DNA (mtDNA) is exclusively maternally inherited, whereas nuclear DNA follows 
Mendelian inheritance. The frequency of cardiac involvement in mitochondrial disease 
is 17–40%, and the estimated prevalence of inherited mitochondrial disease is at least 
1 in 5,000 births [80]. More than 40 different types of mitochondrial disease have 
been associated with the development of HCM. Many forms of mitochondrial disease 
associated with HCM present during infancy. Because diagnosing mitochondrial 
disease can be challenging for clinicians, it is recommended that a multidisciplinary 
team (including a geneticist or mitochondrial specialist) be involved in the diagnosis 
and management [81]. Mitochondrial CM is characterized by abnormal heart-
muscle structure, function, or both. These abnormalities result from genetic defects 
involving mitochondrial activity in the absence of concomitant coronary artery 
disease, hypertension, valvular disease, or CHD. The typical cardiac manifestations of 
mitochondrial disease include the presence of arrhythmias, hypertrophic HCM, LVNC 
and DCM. Worsening cardiovascular disease may occur during a metabolic crisis 
[80–82].
Barth syndrome, described earlier in this chapter, is an X-linked disorder 
caused by pathogenic variants in the TAZ gene on chromosome Xq28, resulting in 
an inborn error of lipid metabolism, cardiolipin deficiency, 3-methylglutaconic 
aciduria, and cyclic neutropenia. BTS patients may occasionally develop any form 
of CM, including HCM [32].
2.2.2.2.6 MELAS
MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like 




nonobstructive concentric hypertrophy (HCM), although DCM, Wolff-Parkinson-
White (WPW) syndrome, and atrial tachycardia have also been reported [83–85]. 
Several genes have been postulated to cause MELAS, including the ones listed in 
Table 3.
2.3 Left ventricular noncompaction cardiomyopathy
LVNC is characterized by the presence of trabeculations, deep intertrabecular 
recesses, and a thin compacted myocardial layer in the left, right, or both ventricles. 
The incidence of LVNC is unknown, but some studies estimate 0.014% to 1.3% 
in the general population [4]. However, with improved echocardiographic and 
cardiac MRI quality and increasing awareness of LVNC in recent years, the 
incidence is likely underestimated [34]. Clinically, nine forms of LVNC have 
been described as follows: [1] the “benign” form of LVNC with normal systolic 
function, normal chamber sizes and thickness, and no history of arrhythmias; 
[2] the arrhythmogenic form of LVNC; [3] the DCM form of LVNC; [4] the HCM 
form of LVNC; [5] the mixed/undulating CM form of LVNC; [6] the RCM form 
of LVNC; [7] the biventricular noncompaction CM form; [8] the right ventricular 
noncompaction form (RVNC); and [9] LVNC associated with congenital heart 
disease [34, 81, 86, 87]. The various phenotypes are depicted in Figure 4. The 
clinical presentation may range from asymptomatic to a severe course accompanied 
by heart failure requiring heart transplant, arrhythmias, sudden cardiac death, 
and thromboembolic phenomena [88]. Familial cases are well-documented, and 
autosomal dominant transmission is the most common inheritance pattern (with 
variable penetrance and phenotypic heterogeneity). Other modes of inheritance 
include X-linked, autosomal recessive, and mitochondrial [43]. In pediatric and 
adult cohorts, the diagnostic rate of gene testing in patients with LVNC ranges 
from 17–41% depending on patient selection and the number of genes screened. 
An estimated 18 to 50% of probands have a family member with LVNC [89, 90]. 
One of the first genetic causes of isolated LVNC was described in 1997 in the gene 
G4.5/TAZ located at chromosome Xq28 [88]. Since then, multiple pathologic 
gene variants have been described as potential causes of LVNC. Genes encoding 
sarcomeric and cytoskeletal proteins (TTN, ACTN2, RBM20, LMNA, DES, 













Genes associated with MELAS [83–85].
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cardiac morphogenesis (FKBP12, MIB1, Tbx20, Nkx2-5, Smad7, NF-ATc, Jarid2), 
ion channels (SCN5A, HCN4, RYR2), and mitochondria (NNT, TAZ) have been 
implicated in the development of LVNC [90–93]. Along with sarcomere-encoding 
and cytoskeleton-encoding genes, pathogenic variants in a variety of genes, 
including SCN5A, LMNA, RBM20, TTN, and DES, have been associated with 
LVNC and rhythm disturbance [94–95]. In addition, homozygous deletions in 
desmoplakin (DSP) and plakophilin 2 (PKP2)—desmosomal protein-encoding 
genes that cause arrhythmogenic CM and DCM—have been identified in LVNC 
patients [96]. Moreover, mutations in the mitochondrial genome and chromosomal 
abnormalities have been associated with LVNC, including 1p36 deletion, 7p14.3p14.1 
deletion, 18p subtelomeric deletion, 22q11.2 deletion, distal 22q11.2, trisomies 18 
and 13, 8p23.1 deletion, and tetrasomy 5q35.2-5q35 (Table 4) [34, 47, 91, 97–99].
Additionally, LVNC has been associated with several genetic syndromes and 
inborn errors of metabolism such as Coffin-Lowry syndrome, Sotos syndrome, 
Charcot–Marie–Tooth disease, Noonan syndrome, and BTS [100–103]. A recent study 
also demonstrated a higher prevalence of LVNC among patients with heterotaxy than 
among the general population, suggesting possible common genetic mechanisms [104].
2.4 Arrhythmogenic Cardiomyopathy (ACM)
This CM is an arrhythmogenic myocardial disorder not explained by ischemia, 
hypertension, or valvular heart disease. ACM was previously referred to as 
Figure 4. 
LVNC phenotypes. (A) Echocardiographic 4-chamber view displays the benign type of LVNC characterized by 
the cardinal feature of left ventricular trabeculations (arrow) with normal anatomy and function; (B) cardiac 
magnetic resonance (cMRI) 4-chamber view displays the dilated type of LVNC, notice the enlargement of 
the LV and the presence of apical and lateral trabeculations (arrow); (C) echocardiographic 4-chamber view 
shows the hypertrophic type of LVNC represented by asymmetric hypertrophy of the interventricular septum 
and the presence of lateral LV trabeculations (arrow); (D) echocardiography displaying the restrictive type 
of LVNC, notice the significant bilateral atrial enlargement (arrows) and the left ventricular dysfunction 
showing spontaneous cavitary contrast; (E) echocardiography shows features suggestive of bilateral ventricular 
hypertrabeculations (arrows); (F) cMRI in a short axis view displays a mixed LVNC phenotype represented 























Gene Protein Pattern of 
Inheritance
Disease Association OMIM# Locus
ACTC1 Actin, Alpha, Cardiac Muscle AD LVNC, ACM, HCM, DCM 102540 5q31.1
CASQ2 Calsequestrin 2 AR, AD LVNC 114251 6q22.31




AD LVNC 605206 18q12.1
LDB3 Lim Domain-Binding 3 AD LVNC, ACM, HCM, DCM 605906 2p22.1
LMNA Lamin A/C AD, AR LVNC, ACM, HCM, DCM 150330 1q22
MIB1 E3 Ubiquitin Protein Ligase 1 AD LVNC 608677 22q11.21
MYBPC3 Myosin-Binding Protein C, Cardiac AD LVNC, RCM, HCM, DCM 600958 Xq28
MYH7 Myosin, Heavy Chain 7, Cardiac Muscle, Beta AD LVNC, RCM, HCM, DCM 160760 7p14.2
PRDM16 Pr Domain-Containing Protein 16 AD LVNC, DCM 605557 6q21
TAZ Tafazzin AR, XL LVNC, DCM 300394 Xq24
TBX20 T-Box 20 AD LVNC, DCM 606061 10q22.3-q23.2
TNNT2 Troponin T Type 2 (Cardiac) AD LVNC, RCM, HCM, DCM 191045 17q12
VCL Vinculin AD LVNC, HCM, DCM 193065 10q25.2
AD – Autosomal dominant; AR – Autosomal Recessive; XL – X-linked; DCM – Dilated cardiomyopathy; HCM – Hypertrophic cardiomyopathy; LVNC – Left ventricular non-compaction cardiomyopathy; 
ACM – Arrhythmogenic cardiomyopathy; RCM – Restrictive cardiomyopathy.
Table 4. 
List of common genes and patterns of inheritance in LVNC.
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arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD, ARVC). 
The reported prevalence of ACM is as common as 1 in 1,000-5,000 people [105]. 
The clinical diagnosis may be supported by evidence of conduction disease, 
supraventricular arrhythmias, and/or ventricular arrhythmias originating from any 
cardiac structure. ECG abnormalities include right bundle branch block pattern, an 
epsilon wave (defined as a low-amplitude deflection located between the end of the 
QRS and the onset of the T wave in leads V1–V3), and T wave inversion(s) recorded 
in leads V1–V4. Classically, the RV is dilated and contains fibro-fatty infiltration 
of the myocardium. The left ventricle is overtly affected with less frequent 
involvement. Notably, ACM clinically overlaps with other CM types, particularly 
DCM. However, ACM is distinct in that it is marked by arrhythmia at presentation 
with or without biventricular dilation and/or impaired systolic function [106]. 
This heritable disorder is usually transmitted in an autosomal dominant pattern 
(with variable penetrance), although autosomal recessive patterns reportedly 
affect junctional plakoglobin (JUP) and desmoplakin (DSP) in families with 
cardiocutaneous disease from Greece, Italy, India, Ecuador, Israel, and Turkey [107]. 
The most notable autosomal recessive diseases include Naxos disease (a homozygous 
pathogenic variant in the gene encoding the protein plakoglobin characterized by 
ACM, a non-epidermolytic palmoplantar keratoderma, and wooly hair) and Carvajal 
syndrome (caused by a homozygous pathogenic gene variant that truncates the 
DSP protein) [107, 108]. Analysis of first- and second-degree relatives of patients 
with ACM suggest that up to 50% of ACM cases are familial [109]. Pathogenic gene 
variants within the desmosomal proteins are the main cause of “classic” ACM [110]. 
Pathogenic gene variants in the three main classes of desmosomal proteins account 
for 60% of affected patients [111]. Overall, the three groups of desmosomal proteins 
include transmembrane desmosomal cadherins (including DSC2 and DSG2), 
DSP (a plakin family protein that attaches directly to the intermediate filament 
desmin in the myocardium), and linker proteins such as armadillo family proteins 
(including JUP and PKP2 that mediate interactions between the desmosomal 
cadherin tails and DSP) [112]. Pathogenic variants in the PKP2, DSP and DSG2 
genes are found in approximately 80% of classic ACM cases [112]. Overall, the most 
commonly mutated gene is plakophilin, which accounted for 46–61% of patients 
from two different registries [113]. In addition to desmosomal proteins, genes 
encoding proteins that interact with these desmosomal proteins have been found 
in ACM. These proteins include: transforming growth factor β3 (TGF-β3), which 
conveys cytokine-stimulating fibrosis and modulates cell adhesion and growth; 
transmembrane protein 43 (TMEM43), an adipogenic transcription factor; DES, 
which binds DSP; and TTN, which bridges the sarcomere along its longitudinal axis 
and forms a continuous filament along the myofibril [18]. To date, approximately 18 
causative genes involved in ACM have been identified [106, 109], please see Table 
5. Notably, compound and digenic heterozygosity is involved in ACM pathogenesis 
in up to 20% of cases and leads to more severe disease [114, 115]. Sarcoidosis and 
Brugada syndrome are commonly mistaken for ACM.
2.5 Restrictive cardiomyopathy (RCM)
RCM is rare, accounting for approximately 5% of all CMs. RCM is characterized 
by normal or decreased volume of both ventricles associated with atrial enlarge-
ment (left or bi-atrial), normal LV wall thickness, normal atrioventricular valve 
function/structure, impaired ventricular filling with restrictive physiology, and 
normal (or near normal) systolic function, please see Figure 5 [4, 116].
The clinical course is defined by the inability to fill the ventricles due to poor 






















Gene Protein Pattern of 
Inheritance
Disease Association OMIM# Locus
ACTC1 Actin, Alpha, Cardiac Muscle AD ACM, HCM, DCM, LVNC 102540 5q31.1
ARVD3 Arrhythmogenic Right Ventricular Dysplasia, Familial, 3 AD ACM 602086 12p12.1
ARVD4 Arrhythmogenic Right Ventricular Dysplasia, Familial, 4 AD ACM 602087 15q14
ARVD6 Arrhythmogenic Right Ventricular Dysplasia, Familial, 6 AD ACM 604401 1q42-q43
CTNNA3 Catenin Alpha 3 AD ACM 607667 7q21.2
DES Desmin AD,AR ACM, RCM, DCM 125660 17q21
DSC2 Desmocollin 2 AD, AR ACM, DCM 600271 Xq22
DSG2 Desmoglein 2 AD ACM, DCM 125671 15q24.1
DSP Desmoplakin AD, AR ACM, DCM 125485 11p15.5
FLNC Filamin C AD ACM, DMC, RCM, HCM 102565 10q22.2
JUP Junction Plakoglobin AD, AR ACM 173325 2p13.1
LDB3 Lim Domain-Binding 3 AD ACM, HCM, DCM, LVNC 605906 2p22.1
LMNA Lamin A/C AD, AR ACM, HCM, DCM, LVNC 150330 1q22
PKP2 Plakophilin 2 AD ACM, DCM 602861 11p15.4
PLN Phospholamban AD ACM, HCM, DCM 172405 4q12
RYR2 Ryanodine Receptor 2 (Cardiac) AD ACM, HCM 180902 12p11
SCN5A Sodium Channel, Voltage-Gated, Type V, Alpha Subunit AD ACM, DCM 600163 20q13.12
TGFB3 Transforming Growth Factor Beta 3 AD ACM 190230
TMEM43 Transmembrane Protein 43 AD ACM 612048 10q23.3
TTN Titin AD, AR ACM, HCM, DCM 188840 5q33-q34
AD – Autosomal dominant; AR – Autosomal Recessive; XL – X-linked; DCM – Dilated cardiomyopathy; HCM – Hypertrophic cardiomyopathy; LVNC – Left ventricular non-compaction cardiomyopathy; 
ACM – Arrhythmogenic cardiomyopathy; RCM – Restrictive cardiomyopathy.
Table 5. 
List of common genes and patterns of inheritance in ACM.
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with exercise intolerance, dyspnea, edema, atrial fibrillation, syncope, or sudden 
cardiac death. The hallmark of non-invasive imaging is atrial or bi-atrial enlarge-
ment. Normal or mild concentric hypertrophy with normal or reduced ventricular 
cavity can also be seen. Familial disease has been reported in 30% of cases and 
usually exhibits autosomal dominant inheritance. However, autosomal recessive, 
X-linked, and mitochondrial-transmitted disease have also been reported [117]. 
Most patients with RCM harbor gene mutations in sarcomere-encoding genes, such 
as TNNI3 (most common), TNNT2, MYH7, ACTC1, TPM1, MYL3, and MYL2, see 
Table 6 [18, 118]. Gene variants in the desmin gene have been reported in associa-
tion with atrioventricular block and skeletal myopathy [119, 120].
RCM can be classified based on the underlying process: non-infiltrative; 
infiltrative; associated with storage diseases; idiopathic; or combined with DCM, 
HCM, and LVNC [116]. As with DCM, many previous cases deemed idiopathic 
are later found to harbor causative pathogenic variants in sarcomeric genes. Non-
infiltrative causes of RCM include scleroderma and systemic sclerosis with well-
described polymorphisms in genes coding for ECM proteins [121]. Pseudoxanthoma 
elasticum is an inherited disorder associated with accumulation of mineralized 
elastic fibers that may lead to blindness, coronary arterial occlusive disease, and 
RCM. The ABCC6 gene on chromosome 16p13.1 is responsible for the calcification 
of elastic fibers [122]. Infiltrative causes of RCM include amyloidosis, a group of 
diseases characterized by extracellular deposition of insoluble fibrillar proteins with 
concomitant destruction of normal tissue structure and function. Approximately 
20 different proteins cause cardiac amyloidosis. In the hereditary disease type, more 
than 100 gene mutations are known at present [123, 124]. The Val122Ile variant of 
transthyretin (TTR) is the most common [125]. Sarcoidosis can also cause systolic 
dysfunction and arrhythmias. The strongest genetic associations are found within 
the human leucocyte antigen (HLA) gene and functional polymorphisms within 
the butyrophilin-like 2 (BTNL2) gene [126].
Lysosomal storage disorders are characterized by abnormal lysosomal metabo-
lism leading to accumulation of various glycosaminoglycans, glycoproteins, or 
glycolipids within lysosomes of various tissues, including the myocardium. Gaucher 
Figure 5. 
Two-dimensional, apical 4-chamber echocardiographic image depicting small, restrictive ventricles and 




disease and Fabry disease (two of the most common lysosomal disorders) may 
manifest as CM (HCM or RCM), valvular disease, coronary artery disease, and/or 
aortic enlargement [127].
Mucopolysaccharidoses (Hurler and Hunter diseases) are characterized by the 
deficiency of enzymes required for the breakdown of glycosaminoglycans. Thus, 
these diseases are considered lysosomal storage disorders. Cardiac manifestations 
start from childhood and include RCM, endocardial fibroelastosis, and valvular 
disease including thickening of the leaflets with resultant stenosis and/or insuf-
ficiency. Storage diseases such as hemochromatosis (mutation in the HFE gene) 
cause a mixture of systolic and diastolic dysfunction often accompanied by arrhyth-
mias [128].
In summary, CM is a widely variable disease process with a similarly vari-
able pattern of genetic inheritance. Our understanding of the interplay between 
genetic mutation and disease phenotype is ever-evolving and merits much deeper 
investigation.







AD LVNC, HCM, 
DCM
603883 14q24.3
DES Desmin AD, AR RCM, DCM, 
ACM
125660 17q21
FLNC Filamin C AD RCM, HCM, 
ACM, LVNC
102565 10q22.2
MYBPC3 Myosin-Binding Protein 
C, Cardiac
AD RCM, HCM, 
DCM, LVNC
600958 Xq28
MYH7 Myosin, Heavy Chain 7, 
Cardiac Muscle, Beta
AD RCM, HCM, 
DCM, LVNC
160760 7p14.2
MYL3 Myosin, Light Chain 
3, Alkali, Ventricular, 
Skeletal, Slow
AD, AR RCM, HCM 160790 1q32
MYOZ2 Myozenin 2 AD RCM, HCM, 
DCM
605602 3p25.1
MYPN Myopalladin AD RCM, HCM, 
DCM
608517 12q23.1
TNNI3 Troponin I Type 3 
(Cardiac)
AD RCM, HCM, 
DCM
191044 3p21.1
TNNT2 Troponin T Type 2 
(Cardiac)
AD RCM, HCM, 
DCM, LVNC
191045 17q12
TPM1 Tropomyosin 1 (Alpha) AD RCM, HCM, 
DCM
191010 19q13.4
AD – Autosomal dominant; AR – Autosomal Recessive; XL – X-linked; DCM – Dilated cardiomyopathy; HCM – 
Hypertrophic cardiomyopathy; LVNC – Left ventricular non-compaction cardiomyopathy; ACM – Arrhythmogenic 
cardiomyopathy; RCM – Restrictive cardiomyopathy.
Table 6. 
List of common genes and patterns of inheritance in RCM.
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